Genome-Wide Assessment of Streptococcus agalactiae Genes Required for Survival in Human Whole Blood and Plasma.
Luchang ZhuPrasanti YerramilliLayne PruittMatthew Ojeda SaavedraConcepcion C CantuRandall J OlsenStephen B BeresAndrew S WallerJames M MusserPublished in: Infection and immunity (2020)
Streptococcus agalactiae (group B streptococcus, or GBS) is a common cause of bacteremia and sepsis in newborns, pregnant women, and immunocompromised patients. The molecular mechanisms used by GBS to survive and proliferate in blood are not well understood. Here, using a highly virulent GBS strain and transposon-directed insertion site sequencing (TraDIS), we performed genome-wide screens to discover novel GBS genes required for bacterial survival in human whole blood and plasma. The screen identified 85 and 41 genes that are required for GBS growth in whole blood and plasma, respectively. A common set of 29 genes was required in both whole blood and plasma. Targeted gene deletion confirmed that (i) genes encoding methionine transporter (metP) and manganese transporter (mtsA) are crucial for GBS survival in whole blood and plasma, (ii) gene W903_1820, encoding a small multidrug export family protein, contributes significantly to GBS survival in whole blood, (iii) the shikimate pathway gene aroA is essential for GBS growth in whole blood and plasma, and (iv) deletion of srr1, encoding a fibrinogen-binding adhesin, increases GBS survival in whole blood. Our findings provide new insight into the GBS-host interactions in human blood.
Keyphrases
- genome wide
- dna methylation
- copy number
- genome wide identification
- pregnant women
- endothelial cells
- free survival
- candida albicans
- genome wide analysis
- induced pluripotent stem cells
- ejection fraction
- bioinformatics analysis
- transcription factor
- acute kidney injury
- newly diagnosed
- prognostic factors
- high throughput
- amino acid
- acute respiratory distress syndrome
- multidrug resistant
- small molecule
- septic shock
- gestational age